Mecolzin (Mesalazine)

Mesalazine releases 5‑aminosalicylic acid directly in the colon where it blocks cyclooxygenase and lipoxygenase enzymes, lowering prostaglandin and leukotriene production. It also neutralises free radicals, collectively diminishing the inflammatory response of the intestinal mucosa.

The specific dose of Mecolzin is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions and local prescribing guidelines.

Safety data for mesalazine in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To order Mecolzin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mecolzin delivers mesalazine, the same active moiety found in other 5‑ASA products. Differences may lie in formulation, release characteristics, and dosing convenience. Clinicians choose a specific product based on patient tolerance, required dosing frequency, and cost considerations.

Mecolzin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mecolzin is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. The medication should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, pancreatitis, and interstitial nephritis. Patients should be monitored for signs of these conditions and seek immediate medical attention if symptoms develop.

Mecolzin is contraindicated in individuals with known hypersensitivity to mesalazine, other 5‑ASA compounds, or salicylates. It should also be avoided in patients with severe renal or hepatic impairment unless a specialist determines that benefits outweigh the risks.